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Abstract
Introduction: Nowadays, a significant number of children with acute leukemia can be cured. Iron overload, related to 
blood transfusions and its long-term complications, remains a problem. Elevated ferritin concentration is often observed 
in this group.
The aim of this study was to evaluate the prognostic value of serum ferritin on long-term outcomes in children treated 
for acute leukemia. 
Material: We studied 71 patients treated for acute lymphoblastic (ALL) or myeloblastic (AML) leukemia between 2005 
and 2011. Serum ferritin concentration, serum transaminases activity, lactic dehydrogenase and C-reactive protein 
levels (CRP) were analysed. Serum ferritin >1,000 µg/L was considered to be a marker of iron overload.
Results: Thirty-seven patients (52.1%) had iron overload. Ferritin serum concentration correlated with alanine amino-
tranferase activity (p =0.001) and CRP concentration (p =0.012). A total of 19 (26.76%) patients died during follow-up. 
Ferritin level was higher in patients with AML vs. ALL. There was a significant difference in long-term outcomes with 
respect to high ferritin concentrations, both in patients undergoing haematopoietic cell transplantation (HCT) and in 
the non-HCT group.
Conclusions: In both groups, patients with higher ferritin concentrations had worse overall and event-free survivals and 
a higher relapse incidence. Ferritin concentration >1,000 µg/L was the strongest determinant of long-term treatment 
outcome. Ferritin serum concentration >1,000 µg/L is an adverse prognostic marker of survival in children with acute 
leukemia treated with chemotherapy with or without HCT.
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Introduction
In recent years, a great deal of progress has been made 
in treating acute leukemia in children. Nonetheless, tre-
atment is still complicated by significant morbidity and 
mortality. With improved diagnostic procedures, intensi-
fication of therapy, and effective treatment of infections, 
the prognosis for children with acute lymphoblastic 
leukemia (ALL) and acute myeloid leukemia (AML) has 
improved [1–3]. However, a major challenge has arisen 
regarding long-term complications including iron overload 
and its sequelae [4].
Serum ferritin is usually used to detect iron overload. 
It is a sensitive parameter, albeit of low specificity becau-
se it can be elevated in a variety of inflammatory states, 
as well as other clinical entities including sickle cell ana-
emia [5], haemophagocytic lymphohistiocytosis and macro-
phage activation syndrome [6]. It is also a surrogate marker 
for cytokine release syndrome [7] and neuroblastoma [8]. 
The incidence of hyperferritinemia increases with the 
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AML were treated according to the IDA-FLAG/FLAG 
protocol.
Transplant procedures
Children were qualified for HCT according to chemotherapy 
protocols. The conditioning regimen before transplantation 
was either myeloablative (MAC) or reduced intensity condi-
tioning (RIC). MAC was based on total body irradiation (TBI), 
busulfan or treosulfan. RIC was based on fludarabine or 
busulfan at doses of ≤8 mg/kg/cycle. For prophylaxis of 
graft-versus-host disease (GvHD), cyclosporine A (CsA) and 
short-term methotrexate (MTX) were used. Patients from 
alternative donors [i.e. matched unrelated donor (MUD), 
mismatched unrelated donor (MMUD), or haploidentical 
donor] received anti-thymocyte globulin (ATG).
Definitions
The primary endpoint was overall survival (OS). Additional 
endpoints were event-free survival (EFS) and relapse inci-
dence (RI). An event was defined as relapse or death from 
any cause. EFS was defined as survival without evidence 
of relapse or progression. Relapse was considered in the 
presence of >5% bone marrow (BM) blasts and/or the re-
appearance of the underlying disease. OS was analysed for 
non-HCT patients as the time from the start of chemotherapy 
to death from any cause, or until the end of follow-up; OS for 
transplanted patients was calculated from the day of allo-
-HCT to death from any cause or until the end of follow-up. 
Death from any cause was regarded as an event for OS, while 
relapse and death from any cause were considered to be 
events for EFS. RI was estimated by considering a relapse 
or the reappearance of the underlying disease as events of 
interest, and death without relapse as a competing event.
Statistical analysis
The Mann-Whitney U-test was used for non-categorical com-
parisons and Chi-square or Fisher exact test for categorical 
comparisons. Correlations between laboratory parameters 
were analysed with Spearman rho coefficient. OS, EFS and 
RI were calculated with the Kaplan-Meier curves method, 
and differences between the curves were compared by log-
-rank test. Mean survival was determined by Kaplan-Meier 
method. The Cox regression model was used to calculate 
treatment outcomes for risk factors, and hazard ratios (HR) 
were calculated with 95% confidence interval (95%CI). 
All the tests were two-sided. Statistical significance was 
defined as p <0.05. Am SPSS25 (IBM, Armonk, NY, USA) 
statistical package was used.
Results
Demographics
Our study included 71 patients with acute leukemia, 43 
boys and 28 girls with a median age of 9 (range 1–19.7) 
number of transfusions. One red blood cell (RBC) unit ad-
ministered to correct anaemia contains 200–250 mg of 
iron which is being delivered to the patient. Iron overload 
can occur after 10–20 RBC transfusions. It is universally 
recognised that iron overload is a risk factor for organ and 
metabolic complications. Dysfunction of the heart and li-
ver are commonly observed [9].
Serum ferritin concentration has been shown to be 
a strong predictor of survival after allogeneic haemato-
poietic cell transplantation (allo-HCT) [5, 8, 10, 11]. Apart 
from acute leukemia patients, iron overload resulting from 
transfusion-dependent conditions is frequently observed 
in patients with myelodysplastic syndromes (MDS). In that 
group, elevation of serum ferritin is associated with a high 
risk of leukemic transformation [12].
Data regarding the impact of serum ferritin concentra-
tion on treatment in children with acute leukemia or un-
dergoing HCT is scarce. Thus, the objective of this study 
was to evaluate the prognostic value of serum ferritin con-
centration on the long-term treatment results in children 
with acute leukemia who were undergoing intensive che-
motherapy with or without HCT.
Material
Study design
In this retrospective single centre study, all patients treated 
in our department for acute leukemia between 2005 and 
2011 who were tested for ferritin serum concentration were 
included. Children undergoing multiagent chemotherapy 
with or without subsequent HCT were qualified for long-term 
follow-up. This study was approved by the Local Bioethical 
Committee (169/2020; 31 March 2020).
Collection of data
Serum ferritin concentration, serum transaminases activity, 
and C-reactive protein (CRP) levels  were analysed among 
the study participants. In all cases, ferritin concentration 
was measured at least four months after the diagnosis of 
leukemia. In cases of multiple testing, the highest concen-
tration was taken into account. Serum ferritin >1,000 µg/ 
/L was considered to be a marker of iron overload. The 
values of CRP, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), and lactate dehydrogenase (LDH) 
obtained at closest proximity to the day of ferritin concen-
tration testing were also analysed. In most cases, the time 
interval between these tests was four days or less.
Treatment of leukemia
Children with de novo ALL were treated according to the 
ALL-IC-2002 protocol. Children with relapsed ALL were 
treated according to the ALL-REZ BFM 2002 protocol. 
Children with de novo AML were treated according to 
the AML-BFM-2004 protocol. Children with relapsed 
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years. The primary disease in these patients was ALL in 
54, and AML in 17 (Table I). The total number of patients 
who underwent HCT was 34, comprising 32 allo-HCT and 
two auto-HCT. In 19 patients a MUD, and in 13 a matched 
sibling donor (MSD) transplant was performed. In one 
patient, auto-HCT was followed by allo-HCT; this patient 
was categorised as allo-HCT. The stem cell source for HCT 
was peripheral blood (19 patients) and bone marrow (15 
patients).
Ferritin concentration
The median value of highest serum ferritin concentrations 
was 2,307 µg/L (range: 33–8,500 µg/L) and 708.44 µg/L 
(range: 14–7,440 µg/L) in patients with AML and ALL, 
respectively. In 37/71 patients, serum ferritin was >1,000 
µg/L. Ferritin serum concentration correlated with ALT 
activity (Spearman’s rho coefficient 0.41; p =0.001), and 
CRP concentration (rho 0.32; p =0.012), but not with AST 
activity or LDH concentration.
Survival of patients
Overall, 52 (73%) patients were alive at the end of the study 
in 2020. Mean survival was 9.0 years (95%CI =7.8–10.1). 
Probability of overall survival (pOS) of all patients at 
5 years was 0.79 ±0.05, and at 10 years it was pOS =0.63 
±0.10; the 5-year EFS was 0.70 ±0.06, and the 5-year RI 
was 0.19 ±0.05.
Splitting the analysis into subgroups with respect to 
the highest serum ferritin concentrations, the values of 
probability of OS, EFS and RI are set out in Table II. Pa-
tients with a higher ferritin concentration, regardless of 
its cut-off value, had worse overall survival and a higher 
incidence of relapses.
Table I. Patient characteristics









23 (62.2):14 (37.8) 0.205
Gender
Male:female 43 (60.6):28 (39.4) 23 (67.6):11 (32.4) 20 (54.1):17 (45.9) 0.245
Type of leukemia
ALL:AML 54 (76.1):17 (23.9) 18 (52.9):16 (47.1) 36 (97.3):1 (2.7%) <0.001
Ferritin [µg/L] 461 (4–8,500) 1,060 (14–8,500) 284 (15–2,110) 0.002
ALT [U/mL] 20 (6–1,172) 33 (9–769) 14 (6–1,172) <0.001
AST [U/mL] 30 (11–554) 40 (13–415) 26 (11–554) 0.054
CRP [mg/mL] 7 (<5–374) 10 (<5–146) 5 (<5–374) 0.215
LDH [U/mL] 297 (5–4,705) 341 (113–2,815) 5 (257–4,705) 0.473
ALL — acute lymphoblastic leukemia; AML — acute myeloblastic leukemia; ALT — alanine aminotransferase; AST — aspartate aminotransferase; CRP — C-reactive protein; LDH — lactate dehydrogenase


























































































Total 71 0.79 ±0.05 0.70 ±0.06 0.19 ±0.05
OS — overall survival; EFS — event-free survival; RI — relapse incidence
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Long-term outcomes and differences  
between HCT and non-HCT patients
Patients undergoing HCT (n =34) vs. non-HCT (n =37) had 
significant differences in long-term outcomes, although in 
both groups those with a higher ferritin concentration had 
worse survival. The outcomes for a ferritin concentration 
threshold value of 1,000 µg/L are shown (Figure 1A–I). 
The OS values for non-HCT patients were insignificant 
compared to those with higher vs. lower ferritin (Figure 1B), 
but EFS values were significantly lower for those with high 
ferritin (Figure 1E). This was caused by the higher relapse 
incidence (Figure 1H). For HCT patients, all outcomes were 
significantly worse in patients with a high ferritin concen-
tration (Figure 1C, F, I).
Risk factor analysis
We conducted univariate analysis of factors contributing 
to overall survival including the following parameters: age 
of patient (<10 vs. >10 years), primary diagnosis (ALL vs. 
AML), ferritin serum concentration (<1,000 vs. >1,000 µg/ 
/L), and HCT treatment (non-HCT vs. HCT) (Table III). 
Adverse risk factors with a p <0.1 value were inclu-
ded into multivariate analysis: diagnosis of AML, ferritin 
concentration >1,000 µg/L, and treatment with HCT. The 
only significant risk factor in multivariate analysis was fer-
ritin concentration >1,000 µg/L, with a 7.1-fold hazard risk 
for death. Analogically, ferritin concentration >1,000 µg/ 
/L was the only significant risk factor for EFS and RI with 
a 4.3-fold and a 6.9-fold hazard risk, respectively, for 
adverse events and leukemic relapse (Tables IV and V).
Discussion
Our analysis shows that iron overload is often observed in 
paediatric patients with acute leukemia who are undergoing 
intensive chemotherapy with or without HCT. Furthermore, 
we have shown an adverse prognostic value of ferritin se-
rum concentration. This parameter can be used as a marker 
negatively influencing overall survival, EFS and relapse 
incidence in children after treatment for acute leukemia, 
particularly those undergoing HCT. Previous data has con-
firmed the predictive power of serum ferritin concentration 
for survival after allo-HCT and showed that elevated ferritin 
is associated with an increased risk of relapse [10].
Univariate and multivariate analysis showed that 
high ferritin serum concentrations were correlated with 
Table III. Univariate and multivariate risk factors analysis for overall survival (OS)
Parameter Characteristics 5-year OS Univariate analysis Multivariate analysis
HR (95%CI) p HR (95%CI) p
Age <10 years 0.82 ±0.06 1 0.339 – –
>10 years 0.75 ±0.08 1.6 (0.7–3.9) –
Diagnosis ALL 0.83 ±0.05 1 0.076 1 0.762
AML 0.65 ±0.12 2.3 (0.9–5.7) 1.2 (0.4–3.1)
Ferritin <1,000 µg/L 0.90 ±0.04 1 <0.001 1 <0.001
>1,000 µg/L 0.55 ±0.11 6.8 (2.8–20) 7.1 (2.6–20)
Treatment Non-HCT 0.92 ±0.05 1 0.009 1 0.165
HCT 0.65 ±0.08 5.5 (1.6–18) 2.4 (0.7–10)
HR — hazard ratio; 95%CI — 95% confidence interval; ALL — acute lymphoblastic leukemia; AML — acute myeloblastic leukemia; HCT — haematopoietic cell transplantation
Table IV. Univariate and multivariate risk factors analysis for event-free survival (EFS)
Parameter Characteristics 5-year EFS Univariate analysis Multivariate analysis
HR (95%CI) p HR (95%CI) p
Age <10 years 0.79 ±0.07 1 0.110 – –
>10 years 0.58 ±0.09 2.0 (0.8–4.1) –
Diagnosis ALL 0.77 ±0.06 1 0.044 1 0.753
AML 0.47 ±0.12 2.4 (1.1–5.5) 1.3 (0.4–2.8)
Ferritin <1,000 µg/L 0.86 ±0.05 1 <0.001 1 0.003
>1,000 µg/L 0.32 ±0.10 6.8 (2.8–16) 4.3 (1.6–12)
Treatment Non-HCT 0.89 ±0.05 1 0.002 1 0.111
HCT 0.48 ±0.09 4.9 (1.9–13) 2.5 (0.8–7.3)
HR — hazard ratio; 95%CI — 95% confidence interval; ALL — acute lymphoblastic leukemia; AML — acute myeloblastic leukemia; HCT — haematopoietic cell transplantation
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decreased survival. This finding aligns with previous data 
suggesting iron overload to be strongly correlated with 
a poor prognosis in patients with MDS or after HCT [12]. 
Data on children undergoing non-HCT treatment for leuke-
mia and other types of malignancy is inconsistent, with iron 
overload rates ranging from 24–90% of children (according 
to [13]), and the clinical consequences of iron overload with 
respect to risk groups require additional research. As yet, 
there are no clear guidelines in terms of recommendations 
for iron overload screening.
Our study has several limitations. It was a retrospective 
study, meaning that other possible factors influencing iron 
metabolism could not be taken into account [14]. Also, the 
impact of disease stage and other possible therapy com-
plications [15–19] were not analysed. The validity of the 
assessment of ferritin as an indicator related to the clinical 
course of the disease after treatment in paediatric leuke-
mia is debatable, because serum ferritin might normalise 
during follow-up in some children [20]. Another concern 
is the measurement of parameters in different time inter-
vals of blood samples. The number of administered trans-
fusions also was not taken into consideration. Our group 
of patients was heterogeneous in terms of disease stage 
and donor type.
Based on our results, we propose the monitoring of 
ferritin and iron concentrations in all patients with acute 
leukemia, especially those after the consolidation phase 
of chemotherapy and those undergoing HCT. Ferritin level 
>1,000 µg/L should be taken into account as a significant 
prognostic factor of death.
Conclusion
In conclusion, a high ferritin concentration is an adverse 
prognostic factor for overall survival and event-free survival, 
and contributes to a higher relapse incidence in children 
after treatment for acute lymphoblastic or myeloblastic 
leukemia.
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